OncLive® On Air
609 episodes — Page 1 of 13
S19 Ep5: Navigating Patient-Centric Treatment Administration Strategies in Myeloma
Oct 9, 20269 min
S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer
Oct 7, 202610 min
S19 Ep3: FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia
Oct 2, 202613 min
S19 Ep2: FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
Sep 30, 202612 min
S19 Ep2: Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma
Sep 30, 202616 min
S19 Ep1: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma
Sep 30, 202614 min
S18 Ep50: Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
Sep 30, 202617 min
S18 Ep49: Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings
Sep 30, 202624 min
S18 Ep48: OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma
Sep 30, 202629 min
S18 Ep47: Dissecting Diagnostic and Management Factors in Systemic Mastocytosis
Sep 29, 202622 min
S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML
Sep 29, 202611 min
S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice
Sep 28, 202640 min
S18 Ep44: Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer
Sep 28, 202611 min
S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management
Sep 25, 202645 min
S18 Ep42: Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer
Sep 24, 202611 min
S18 Ep41: Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC
Sep 24, 202619 min
S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
Sep 23, 202617 min
S18 Ep39: Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond
Sep 21, 202611 min
S18 Ep34: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care
Sep 21, 202622 min
S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care
Sep 17, 202624 min
S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE
Sep 14, 202613 min
S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD
Sep 14, 202628 min
S18 Ep35: The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing
Sep 11, 202631 min
S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC
Sep 4, 202628 min
S18 Ep32: Non–Small Cell Lung Cancer 2026 UPDATE
Aug 31, 202613 min
S18 Ep31: FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC
Aug 28, 202622 min
S18 Ep31: Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD
Aug 28, 202627 min
S18 Ep30: FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO
Aug 27, 20268 min
S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment
Aug 24, 202629 min
S18 Ep28: Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD
Aug 20, 202617 min
S17 Ep75: Key Considerations for Health Equity and Patient-Centered Care in TNBC
Aug 17, 202625 min
S17 Ep77: FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD
Aug 14, 202610 min
S17 Ep76: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD
Aug 7, 202615 min
S17 Ep74: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD
Aug 4, 202623 min
S17 Ep73: From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC
Aug 3, 202625 min
S17 Ep72: FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS
Jul 31, 20267 min
S17 Ep69: Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD
Jul 31, 202610 min
S17 Ep71: Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD
Jul 30, 202624 min
S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD
Jul 30, 202617 min
S17 Ep68: Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD
Jul 29, 202618 min
S17 Ep67: Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD
Jul 28, 202648 min
S17 Ep66: FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD
Jul 28, 20266 min
S17 Ep65: ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD
Jul 28, 202612 min
S17 Ep64: FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH
Jul 28, 20265 min
S17 Ep63: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD
Jul 28, 20269 min
S17 Ep61: Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua Sabari, MD
Jul 24, 202617 min
S17 Ep62: Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management
Jul 24, 202631 min
S17 Ep60: Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia
Jul 23, 202629 min
S17 Ep59: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
Jul 21, 202620 min
S17 Ep58: DLBCL 2026 UPDATE
Jul 20, 202612 min